Abstract:OBJECTIVE:The main aim of this study was to systematically evaluate the efficacy and safety of inhibitors of programmed cell death receptor 1 (PD-1) and its ligand, programmed cell death ligand-1 (PD-L1), in the treatment of advanced non-small cell lung cancer (NSCLC).METHODS:Randomized controlled trials assessing the efficacy of PD-1/PD-L1 inhibitors relative to platinum-based chemotherapy for advanced NSCLC in PubMed, EMBASE, and Cochrane libraries from 2015 to 2020 were searched, along with review of studies at American Society of Clinical Oncology (ASCO) and European society for Medical Oncology (ESMO). Pooled hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) and odds ratios (OR) for adverse events (AE) were calculated using STATA and Revman software.RESULTS:PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly improved OS (HR = 0.82, 95% CI:0.74-0.91, P = 0.01 or HR = 0.74, 95% CI:0.67-0.82, P = 0.001). PD-1/PD-L1 inhibitors alone did not benefit PFS (HR = 0.99, 95% CI: 0.89-1.10, P = 0.892), while combination therapy led to prolonged PFS (HR = 0.61, 95% CI: 0.56-0.67, P < 0.001). Subgroup analysis showed that in NSCLC with PD-L1 ≥ 50%, treatment with PD-1/PD-L1 inhibitors alone significantly improved both PFS and OS. In patients subjected to the combined treatment regimen, we observed significant differences in PFS among groups stratified by PD-L1 expression (p < 0.001), immune drug type (p = 0.029), gender (p = 0.014) and liver metastasis (p = 0.035) and OS among groups stratified by immune drug type (p < 0.001), gender (P = 0.001) and smoking status (P = 0.041). Safety analysis showed that combination therapy increased chemotherapy-induced adverse events (AE), while PD-1/PD-L1 inhibitors alone were associated with a lower incidence of any grade of treatment-related AEs (TRAE). A higher incidence of Grade 3-5 TRAEs and hypothyroidism was observed with PD-1 inhibitors than PD-L1 inhibitors.CONCLUSIONS:First-line treatment of advanced NSCLC with immune monotherapy or immunochemotherapy confers a greater survival benefit than chemotherapy alone. Combination of chemotherapy with PD-1/PD-L1 inhibitors leads to an increase in adverse events, and PD-1 inhibitors offer enhanced survival benefits and fewer adverse events than PD-L1 inhibitors. Remarkably, female patients undergoing combination therapy had longer overall survival than male patients.

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

Clinical and Molecular Characteristics Associated with Efficacy of PD-1/PD-L1 Inhibitors for Solid Tumors: A Meta-Analysis

Impact of Clinicopathological Features on the Efficacy of Immune Checkpoint Inhibitors Plus Conventional Treatment in Patients with Advanced Lung Cancer

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Association of PD‐L1 Expression Status with the Efficacy of PD‐1/PD‐L1 Inhibitors and Overall Survival in Solid Tumours: A Systematic Review and Meta‐analysis

Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

The Association of PD-L1 Expression with the Efficacy of Anti-Pd-1/pd-l1 Immunotherapy and Survival of Non-Small Cell Lung Cancer Patients: a Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review

Efficacy of PD-1/PD-L1 Blockade Monotherapy in Clinical Trials

Efficacy and Safety of Combination PD-1/PD-L1 Checkpoint Inhibitors for Malignant Solid Tumours: A Systematic Review.

Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review

Immunotherapy Combined with Chemotherapy Versus Chemotherapy Alone As the First‐line Treatment of PD‐L1‐negative and Driver‐gene‐negative Advanced Nonsquamous Non‐small‐cell Lung Cancer: an Updated Systematic Review and Meta‐analysis

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors Versus Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer: a Meta Analysis of Randomized Controlled Trials.

Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials

EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis